CP 532623
CP 532623 性质
熔点 | 101.8 °C |
---|---|
沸点 | 523.8±50.0 °C(Predicted) |
密度 | 1.38±0.1 g/cm3(Predicted) |
储存条件 | 2-8°C |
溶解度 | 在DMSO中的溶解度为20mg/mL,澄清 |
形态 | 粉末 |
酸度系数(pKa) | -0.93±0.40(Predicted) |
颜色 | 白色至米色 |
CP 532623 用途与合成方法
CETP
CP-532623 is highly lymphatically transported (28% of dose), and lymphatic transport is closely correlated with drug affinity for ex-vivo lymph lipoproteins or triglyceride emulsions and poorly relates to solubility in mixtures of lipoprotein core and/or surface lipids. CP-532623 alters the kinetics of lymph lipid transport and decreases lymph lipid transport in chylomicrons.
CP-532623 (50 mg; oral administration; adult male greyhound dogs) treatment substantially transports into the lymphatic system (>25% dose) in fed and fasted dogs. Food enhances oral bioavailability (from 44 to 58%, respectively) and the proportion of the absorbed dose transports via the lymph (from 61 to 86% and from 68 to 83%, respectively). Lymphatic triglyceride transport is significantly lower in fed dogs administered CP-532623.
Animal Model: | Adult male greyhound dogs (27-39 kg) |
Dosage: | 50 mg |
Administration: | Oral administration with a long-chain lipid formulation to fed lymphcannulated |
Result: | Substantially transported into the lymphatic system (>25% dose) in fed and fasted dogs. Food enhanced oral bioavailability and the proportion of the absorbed dose transported via the lymph. |
CP 532623 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-04-30 | HY-123039 | CP 532623 | 261947-38-0 | 5mg | 2160 |
2024-01-25 | HY-123039 | 1 mg | 2090 |